Maybe, and obviously Wayne is trying to generate leverage with the FDA by doing these compassionate use/special access procedures in Canada but drug companies provide clinical stage drugs to patients for compassionate all the time and no matter the efficacy shown in those patients, the FDA still requires those companies to go stepwise through trial phases to gain approvals.
I can't emphasize enough the fact that there's a reason the FDA requires pivotal studies of around 1000 patients before novel valves can be approved: safety, safety, safety. There are no shortcuts when it comes to validating the safety of life-sustaining devices and trials must have large enough patient populations to prove that the device is safe for widespread use.
Is the Humanitarian Device Exemption for ViV in the US still in play? It's possibly debatable although I've made my opinion known multiple times that there are approved alternatives so I think that door's closed.
This is my projection:
Aug 2024 Pivotal trial start
Feb 2026 Pivotal trial enrollment complete
Feb 2027 Pivotal trial completion
Aug 2027 Premarket Approval submission
Feb 2028 Approval
I'm not trying to be a wet blanket just realistic. I'm definitely not a biotech god so I could be wrong but I think it's a very realistic timeline.
Wayne has talked about going for a CE Mark in Europe, which could be completed faster. I believe he last made those comments at the 2022 AGM but hasn't mentioned anything since that I've heard and running another large trial takes money.
- Forums
- ASX - By Stock
- AVR
- Ann: Exceptional Results in Second Valve-in-Valve Case
Ann: Exceptional Results in Second Valve-in-Valve Case, page-12
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.93 |
Change
-0.290(2.37%) |
Mkt cap ! $252.1M |
Open | High | Low | Value | Volume |
$12.20 | $12.22 | $11.21 | $199.1K | 17.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 577 | $11.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.93 | 131 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 577 | 11.590 |
1 | 890 | 11.550 |
2 | 1080 | 11.500 |
1 | 400 | 11.360 |
1 | 500 | 11.200 |
Price($) | Vol. | No. |
---|---|---|
11.930 | 131 | 1 |
12.250 | 250 | 1 |
12.500 | 1445 | 2 |
12.750 | 3000 | 1 |
12.850 | 1000 | 1 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online